Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.57 |
| ▸ | DRD3 | P35462 | 4/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.57 |
| ▸ | SCN1A | P35498 | 3/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9242920 | 0.90 | CYP3A4 (0.59) | CHRM2ADRA2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL9239838 | 0.89 | SCN1A (0.51) | CHRM2ADRA2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL10549358 | 0.89 | SLC6A3 (0.52) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL10356352 | 0.87 | SCN1A (0.53) | CHRM2ADRA2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL27315712 | 0.86 | SCN1A (0.45) | CHRM2ADRA2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL4667564 | 0.85 | SCN1A (0.65) | CHRM2ADRA2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL6983440 | 0.85 | SCN1A (0.52) | CHRM2ADRA2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL21861456 | 0.84 | SCN1A (0.50) | CHRM2ADRA2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL6981112 | 0.84 | SCN1A (0.50) | CHRM2ADRA2ACHRM1SLC6A2SLC6A4 | |
| SCHEMBL6978977 | 0.84 | SCN1A (0.50) | CHRM2ADRA2ACHRM1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401998-A1 | METHODS OF TREATING CYP2D6 ALTERNATIVE METABOLIZERS | NEKTAR THERAPEUTICS (US) | 2021-12-30 | — | — | US | disclosed |
| US-11033631-B2 | Methods of treating CYP2D6 alternative metabolizers | NEKTAR THERAPEUTICS (US) | 2021-06-15 | — | — | US | disclosed |
| US-20150174264-A1 | Oligomer-Antihistamine Conjugates | NEKTAR THERAPEUTICS (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174264-A1 | Oligomer-Antihistamine Conjugates | NEKTAR THERAPEUTICS (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174264-A1 | Oligomer-Antihistamine Conjugates | NEKTAR THERAPEUTICS (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2121031-B1 | OLIGOMER-ANTIHISTAMINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2121031-B1 | OLIGOMER-ANTIHISTAMINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130053400-A1 | OLIGOMER-ANTIHISTAMINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053400-A1 | OLIGOMER-ANTIHISTAMINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053400-A1 | OLIGOMER-ANTIHISTAMINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2013-02-28 | — | — | US | disclosed |
| EP-0157420-A2 | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1985-10-09 | — | — | EP | disclosed |
| US-4521537-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0111955-A1 | Prostaglandin intermediates | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-06-27 | — | — | EP | disclosed |
| WO-1982000142-A1 | PROSTAGLANDINS | JONES R | 1982-01-21 | — | — | WO | disclosed |
| EP-0043292-A2 | Prostaglandins | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-01-06 | — | — | EP | disclosed |
| US-4265894-A | TREATING PARKINSON'S DISEASE AND ACROMEGALY | GIST BROCADES, N.V. (NL) | 1981-05-05 | — | — | US | disclosed |
| US-4202896-A | DOPAMINERGIC ACTIVITY | GIST-BROCADES N.V. (NL) | 1980-05-13 | — | — | US | disclosed |
| US-3993768-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1976-11-23 | — | — | US | disclosed |
| US-3985889-A | 1,3-DIHYDROSPIRO(ISOBENZOFURAN); ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-10-12 | — | — | US | disclosed |
| US-3962259-A | TRANQUILIZERS, ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174264-A1 | Oligomer-Antihistamine Conjugates | HRH4, HRH1, HRH3 | CHRM2 178/4885ADRA2A 289/4885CHRM1 172/4885 |
| US-20130053400-A1 | OLIGOMER-ANTIHISTAMINE CONJUGATES | HRH4, HRH1, HRH3 | CHRM2 181/4885ADRA2A 262/4885CHRM1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.